Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes

The clinical efficacy of Oxaliplatin (L-OHP) is potentially limited by dose-dependent neurotoxicity and high partitioning to erythrocytes in vivo. Long-circulating liposomes could improve the pharmacokinetic profile of L-OHP and thus enhance its therapeutic efficacy and reduce its toxicity. The purp...

Full description

Bibliographic Details
Main Authors: Nihad Cheraga, Ammar Ouahab, Yan Shen, Ning-Ping Huang
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2021/5949804
id doaj-19464283852e4cfeb0aa021121d57c7c
record_format Article
spelling doaj-19464283852e4cfeb0aa021121d57c7c2021-05-03T00:00:55ZengHindawi LimitedBioMed Research International2314-61412021-01-01202110.1155/2021/5949804Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating LiposomesNihad Cheraga0Ammar Ouahab1Yan Shen2Ning-Ping Huang3State Key Laboratory of BioelectronicsDepartment of PharmaceuticsDepartment of PharmaceuticsState Key Laboratory of BioelectronicsThe clinical efficacy of Oxaliplatin (L-OHP) is potentially limited by dose-dependent neurotoxicity and high partitioning to erythrocytes in vivo. Long-circulating liposomes could improve the pharmacokinetic profile of L-OHP and thus enhance its therapeutic efficacy and reduce its toxicity. The purpose of this study was to prepare L-OHP long-circulating liposomes (L-OHP PEG lip) by reverse-phase evaporation method (REV) and investigate their pharmacokinetic behavior based on total platinum in rat plasma using atomic absorption spectrometry (AAS). A simple and a sensitive AAS method was developed and validated to determine the total platinum originated from L-OHP liposomes in plasma. Furthermore, long-circulating liposomes were fully characterized in vitro and showed great stability when stored at 4°C for one month. The results showed that the total platinum in plasma of L-OHP long-circulating liposomes displayed a biexponential pharmacokinetic profile with five folds higher bioavailability and longer distribution half-life compared to L-OHP solution. Thus, long-circulating liposomes prolonged L-OHP circulation time and may present a potential candidate for its tumor delivery. Conclusively, the developed AAS method could serve as a reference to investigate the pharmacokinetic behavior of total platinum in biological matrices for other L-OHP delivery systems.http://dx.doi.org/10.1155/2021/5949804
collection DOAJ
language English
format Article
sources DOAJ
author Nihad Cheraga
Ammar Ouahab
Yan Shen
Ning-Ping Huang
spellingShingle Nihad Cheraga
Ammar Ouahab
Yan Shen
Ning-Ping Huang
Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
BioMed Research International
author_facet Nihad Cheraga
Ammar Ouahab
Yan Shen
Ning-Ping Huang
author_sort Nihad Cheraga
title Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
title_short Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
title_full Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
title_fullStr Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
title_full_unstemmed Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes
title_sort characterization and pharmacokinetic evaluation of oxaliplatin long-circulating liposomes
publisher Hindawi Limited
series BioMed Research International
issn 2314-6141
publishDate 2021-01-01
description The clinical efficacy of Oxaliplatin (L-OHP) is potentially limited by dose-dependent neurotoxicity and high partitioning to erythrocytes in vivo. Long-circulating liposomes could improve the pharmacokinetic profile of L-OHP and thus enhance its therapeutic efficacy and reduce its toxicity. The purpose of this study was to prepare L-OHP long-circulating liposomes (L-OHP PEG lip) by reverse-phase evaporation method (REV) and investigate their pharmacokinetic behavior based on total platinum in rat plasma using atomic absorption spectrometry (AAS). A simple and a sensitive AAS method was developed and validated to determine the total platinum originated from L-OHP liposomes in plasma. Furthermore, long-circulating liposomes were fully characterized in vitro and showed great stability when stored at 4°C for one month. The results showed that the total platinum in plasma of L-OHP long-circulating liposomes displayed a biexponential pharmacokinetic profile with five folds higher bioavailability and longer distribution half-life compared to L-OHP solution. Thus, long-circulating liposomes prolonged L-OHP circulation time and may present a potential candidate for its tumor delivery. Conclusively, the developed AAS method could serve as a reference to investigate the pharmacokinetic behavior of total platinum in biological matrices for other L-OHP delivery systems.
url http://dx.doi.org/10.1155/2021/5949804
work_keys_str_mv AT nihadcheraga characterizationandpharmacokineticevaluationofoxaliplatinlongcirculatingliposomes
AT ammarouahab characterizationandpharmacokineticevaluationofoxaliplatinlongcirculatingliposomes
AT yanshen characterizationandpharmacokineticevaluationofoxaliplatinlongcirculatingliposomes
AT ningpinghuang characterizationandpharmacokineticevaluationofoxaliplatinlongcirculatingliposomes
_version_ 1714634997570207744